Publications by authors named "Mark Cotton"

Claim this Profile
I
Infectious morbidity among children HIV-exposed uninfected in South Africa.
Kim Anderson, Hlengiwe P Madlala, Dorothy C Nyemba, Ryan Dinkele, Mariette Smith, Mark F Cotton

AIDS· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ART-free HIV-1 remission in children with in-utero HIV-1 after very early ART (IMPAACT P1115): a multicentre, open-label, phase 1/2 proof-of-concept study.
Deborah Persaud, Anne Coletti, Bryan S Nelson, Jennifer Jao, Edmund V Capparelli, Mark Cotton

Lancet HIV· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trial.
Adrie Bekker, Nicolas Salvadori, Helena Rabie, Samantha du Toit, Kanchana Than-In-At, Mark F Cotton

Lancet HIV· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postnatal HIV vertical transmission and the impact of infant feeding choice in the ART era.
Victoria Ndarukwa, Mark Cotton, Moleen Zunza, Lucy Mupfumi, Hans Amukugo

South Afr J HIV Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iron absorption and loss, and efficacy of iron supplementation with and without prebiotics in children with virally suppressed HIV: three prospective studies in South Africa.
Jeannine Baumgartner, Renée Blaauw, Nadja Mikulic, Charlene Goosen, Shaun L Barnabas, Mark F Cotton

Nat Commun· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study.
Marije Van Schalkwyk, Adrie Bekker, Eric Decloedt, Jiajia Wang, Gerhard B Theron, Mark F Cotton

Antimicrob Agents Chemother· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of a care bundle on short peripheral catheter-associated complications in a resource-limited neonatal unit.
Angela Dramowski, Louisa Erasmus, Aaqilah Fataar, Mark F Cotton, Andrew C Whitelaw

J Vasc Access· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential HIV-1 Proviral Defects in Children vs. Adults on Antiretroviral Therapy.
Jenna M Hasson, Mary Grace Katusiime, Adam A Capoferri, Michael J Bale, Brian T Luke, Mark F Cotton

Viruses· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single Doses of Pediatric Dolutegravir Dispersible Tablets in Neonates Support Multidosing: PETITE-Dolutegravir Study.
Tim R Cressey, Nicolas Salvadori, Helena Rabie, Samantha du Toit, Kanchana Than-In-At, Mark F Cotton

J Acquir Immune Defic Syndr· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung Function in the Second Decade of Life in Children after Early HIV Diagnosis and Antiretroviral Therapy Initiation.
Andre G Gie, Marieke M van der Zalm, Eric D McCollum, Sarah Browne, Mark F Cotton

Am J Respir Crit Care Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential HIV-1 Proviral Defects in Children vs. Adults on Antiretroviral Therapy.
Jenna M Hasson, Mary Grace Katusiime, Adam A Capoferri, Michael J Bale, Brian T Luke, Mark F Cotton

bioRxiv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.
Ellen White, Cissy Kityo, Moira J Spyer, Hilda A Mujuru, Immaculate Nankya, Mark F Cotton

Lancet HIV· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized controlled, trial on effects of mobile phone text messaging in combination with motivational interviewing versus standard infant feeding counselling on breastfeeding and child health outcomes, among women living with HIV.
Moleen Zunza, Lehana Thabane, Louise Kuhn, Christine Els, Carl Lombard, Mark F Cotton

Int Breastfeed J· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carotid-Femoral Pulse Wave Velocity in Children in South Africa: Reference Values for the Vicorder Device.
Claire Davies, Florin Vaida, Kennedy Otwombe, Mark F Cotton, Sara Browne

Angiology· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of age and co-medication on dolutegravir glucuronidation in paediatric patients.
Tom G Jacobs, Hylke Waalewijn, Lily Houlden, Pauline D J Bollen, Annet Nanduudu, Mark F Cotton

Br J Clin Pharmacol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living with HIV-1 Treated with Ritonavir-Boosted Fosamprenavir Oral Solution-Based Antiretroviral Therapy.
Lisa L Ross, Mark F Cotton, Haseena Cassim, Harmony P Garges, Sven C van Dijkman

AIDS Res Hum Retroviruses· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium.
Louise Kuhn, Shaun Barnabas, Nicola Cotugno, Holly Peay, Philip Goulder, Mark Cotton

Lancet HIV· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lamivudine dosing for preterm infants exposed to HIV: a population pharmacokinetic modelling and simulation study.
Adrie Bekker, Edmund V Capparelli, Mark Mirochnick, Diana F Clarke, Mark F Cotton

J Antimicrob Chemother· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early inflammation as a footprint of increased mortality risk in infants living with HIV from three African countries.
Elena Morrocchi, Giuseppe R Pascucci, Nicola Cotugno, Chiara Pighi, Sara Dominguez-Rodriguez, Mark F Cotton

Sci Rep· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal controlled attenuation parameter and liver stiffness in children with and without perinatal HIV infection in South Africa.
Penelope C Rose, Claire Davies, Mark F Cotton, Kennedy Otwombe, Sara H Browne

AIDS· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiometabolic Risk Profiles of Adolescents Living With Perinatally Acquired HIV in South Africa.
Leonore Greybe, Shaun Barnabas, Mark Cotton, Penelope Rose, Helena Rabie

Pediatr Infect Dis J· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High mortality following early initiation of antiretroviral therapy in infants living with HIV from three African countries.
Alfredo Tagarro, Sara Domínguez-Rodríguez, Mark Cotton, Kennedy Otwombe, Nigel Klein

EClinicalMedicine· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.
Carina A Rodriguez, Eva Natukunda, Renate Strehlau, Esme L Venter, Supattra Rungmaitree, Mark F Cotton

Lancet HIV· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 antibodies in adolescents living with perinatally acquired HIV.
Lisa Frigati, Leonore Greybe, Shaun Barnabas, Mark Cotton, Helena Rabie

S Afr J Infect Dis· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial.
Adrie Bekker, Nicolas Salvadori, Helena Rabie, Samantha du Toit, Kanchana Than-In-At, Mark F Cotton

Lancet HIV· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis